



R&D Day

DECEMBER 6, 2021





Safe Harbor

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this presentation constitute forward-looking statements, including, without limitation, statements about: the perceived advantages of our products relative to competitive products and technologies; our anticipated growth and other measures of future operating results and financial performance; the development and commercialization of new products; and our ability to secure and maintain necessary regulatory approvals for our existing products and new products under development. Our estimates and forward-looking statements are based on our management's current assumptions and expectations of future events and trends, which affect or may affect our business, strategy, operations or financial performance. These statements are not guarantees of future performance and involve a number of risks and uncertainties, many of which are beyond our control, including the potential impacts of COVID-19. Our actual results may differ materially from those expressed or implied by such forward-looking statements. Some of the factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements can be found under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, as well as in the other reports we file with the Securities and Exchange Commission. In addition, new risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Estimates and forward-looking statements speak only as of the date they were made, and, except to the extent required by law, we undertake no obligation to update or review any estimate and forward-looking statement because of new information, future events or other factors.

NON-GAAP FINANCIAL MEASURES

This presentation references EBITDA, which is a non-GAAP financial measure defined as net income (loss) excluding income taxes, interest and other non-operating items and depreciation and amortization. Adjusted EBITDA further adjusts for the change in fair value of common stock warrants and non-cash stock-based compensation expense. This definition of Adjusted EBITDA may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Adjusted EBITDA is a key measure used by the Company to evaluate operating performance, generate future operating plans and make strategic decisions for the allocation of capital. The Company presents Adjusted EBITDA to provide information that may assist investors in understanding its financial results. However, Adjusted EBITDA is not intended to be a substitute for net loss.

TRADEMARKS


©2021 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, t:flex, t:slim, t:slim G4, t:slim X2, Basal-IQ, Control-IQ, t:lock, micro-delivery, t:connect, touch simplicity and our logos are trademarks, registered trademarks, and/or the subject of a pending trademark application in the U.S. and other territories worldwide. The Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Tandem Diabetes Care is under license. All other trademarks and copyrights are the property of their respective owners.



Our Vision




TANDEM
DIABETES CARE



Positively Different



Expanding our history of “firsts”



Connected mobile app for iOS and Android devices



Rechargeable battery



Remote updateable software



Automated controller enabled FDA designation

Interoperable automated glycemic controller FDA designation

Designation by FDA as compatible with iCGM




Automated correction bolus feature



Touch screen



Relentless...




Innovation

200,000+ people using
Control-IQ™ technology



90,000+
customers
updated software
to Control-IQ



Delivering On Our Commitment




Available in
20+ countries

65+ peer reviewed manuscripts
and published abstracts on t:slim
X2 since 2019

More than
40,000,000 patient
days of Control-IQ
use data



Expanding Ecosystem





Delivery Devices





Device Software





Data & Insights





Transitioning to a Global Ecosystem





Worldwide Installed Base Goal of

**1 million people
living with diabetes**

Q3 2021 Worldwide Installed Base*:
nearly 300,000 customers

R&D Day | December 2021



Market & Strategy

30+ million people on
Intensive Insulin Therapy
(IIT) worldwide

T1D=24mil


T2D=9mil



Sources. Internal estimates. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020. International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes Federation, 2019. <http://www.diabetesatlas.org>




>9 million people on IIT in our target markets



U.S.

~1.6 million
~2.3 million




Outside U.S.

~4 million
~1.5 million





Type 1 Pumpers



+ 1M
New T1D pumpers


Sources. Internal estimates. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020. International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes Federation, 2019. <http://www.diabetesatlas.org>




Type 2 Pumpers

U.S. & Outside

TODAY



2027



+325k
new T2D pumpers



Sources. Internal estimates. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020. International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes Federation, 2019. <http://www.diabetesatlas.org>



+




T1D

T2D




T1D Journey



**The pump is a
fast track**



T2D Journey





1 out of 3 of people living with type 2 and administering insulin through multiple daily injections voiced interest in near-term pump adoption.*

**Tandem sponsored blinded market research: n=650*




It takes a Village:

- ✓ Family
- ✓ Friends
- ✓ Physician
- ✓ Diabetes Educator




Highly Segmented Market






Highly Segmented Market





Strategic Imperatives






Platform Strategy for Continued Long Term Growth



Delivery Devices




t:slim Flagship





t:slim X2



Infusion Sets

- Easier insertion
- Reduced occlusions
- Extended wear
- Increased options
- Reduced body burden
- Less waste



Features under development. Subject to future regulatory submission and clearance.



t:slim X3

- Enhanced technology
- Refreshed user interface
- Increased battery life
- Wireless software updates



Under development. Subject to future regulatory submission and clearance.

R&D Day | December 2021



t:sport Design Goals

- Utilizing modern technologies for battery, charging, and wireless use
- Controlled from a personal smartphone
- Miniaturized form factor with flexible wear options
- FDA submission as an ACE Pump enabling use of Control-IQ and iCGMs with no new clinical data



Under development. Subject to future regulatory submission and clearance.
R&D Day | December 2021



Tandem mobi™ Insulin Pump



Under development. Subject to future regulatory submission and clearance.



Tandem Mobi

- ~50% Of t:slim X2's Size
- 200-unit Cartridge
- Embedded AID Algorithm
- User's Smartphone Control
- Wireless Charging
- Bolus Button
- Waterproof
- iCGM Compatible
- Compatible with current and new 4" infusion set






More than 50% of survey participants chose t:slim or Mobi vs future competitive offerings





Expanding Our Segments Served





Mobi: Tubeless

Under development. Subject to future regulatory submission and clearance.




Mobi: Tubeless




Leverages
Mobi pump

Ultimate in choice
of wearability




Disposable on body kit
replaces the infusion set





Pushing Forward







Patch



Under development. Subject to future regulatory submission and clearance.




Positively Different





Device Software






The Power of AID



Sleeping through the night



Freedom & Reduced Burden

AID Improvement

Growing the Market & Capturing Share

1

Continuous improvement for current Control-IQ users

2

Improve outcomes for people using a pump but not meeting American Diabetes Association guidelines today

3

Attract people using MDI to adopt Control-IQ




Experience Matters




**more hours/day
time spent in range**
(70-180 mg/dL)

9,500 users








In Pursuit of....





Expanding Indications



The Role of Insulins in A1D






Mobile Control Apps





Immediate Access to Innovation



130,000+
TDU Updates



90,000+
Control-IQ Updates



160,000+
App Downloads

Note: Software updates are available to in-warranty customers only. A prescription and additional training may be required to access certain software updates.




Delivering Sensor Choice





Unlocking a Broader Ecosystem





Data & Insights



What Are Data Products?





Physician Panel on Data Insights

Nicholas Argento, MD, FACE



Senior Clinical Endocrinologist and
Diabetes Technology Director at the
Maryland Endocrine and Diabetes Center.

Joyce Lee, MD MPH

Research Professor of Pediatrics at the
University of Michigan Medical School and
School of Public Health. Associate Chief
Medical Information Officer for Pediatric
Research at Michigan Medicine and as
Associate Chair for Health Metrics and
Learning Health Systems for the
Department of Pediatrics.



Tandem Source



The graphics presented on this page are for illustrative purposes only, and do not reflect individual results.




Settings Automation

 "Big Data"
Optimal Model

 CIQ

 CIQ + **Settings Automation**





Why It's a Competitive Advantage


40 million

30 million

20 million

Jan 2020


Present






Why Data Products are Important to Us

Existing
Products
and
Services



Emerging
Products and
Capabilities






Financial Outlook



Focus on Innovation Drives Financial Success





Growth Opportunity Persists

2018: 80K+



2021: 300K+



2027 Goal: 1M





Enhancing Value Proposition

Evidence

+


Customization

=

Optimize
Quality of
Care



Scale and Innovation Drive Margin Performance



*2021 guidance as of November 3, 2021


R&D Day | December 2021



Mobi Manufacturing




Prioritize Investments in Innovation



* 2021 Q3 performance

- R&D longer-term CAGR ~**20%**
- SG&A longer-term CAGR **10%-15%**
- Magnitude of investments may be greater in near-term



Creating Value through Innovation